MARCYRL

How drugs are made?

Pharmaceutical products are made through complex processes involving research, development, manufacturing, and quality control. Here's a simplified overview

1. Research and Development (R&D)

We identify potential drug candidates through research, often targeting specific diseases or conditions. This stage involves testing compounds in laboratories and studies to assess efficacy and safety.

Marcyrl Research and development (R&D) is the key driver in developing and introducing new products to national & international markets improving the population’s overall health and economic situation by reducing hospitalizations and operating costs in the healthcare sector through:

• Pre-clinical research & reaching innovative drug delivery systems.
• Experimental design testing.
• Designing production processes.
• Clinical testing.
• Enhancing & developing new concentrations, dosage forms, and delivery systems.

HF0165OA2940/112024

HF0165OA3115/122024

HDHMF0165OA3309/012025

2. Regulatory Approval:

Ensuring that we comply with local and international regulations & standards. Marcyrl's Regulatory department is responsible for preparing and submitting the necessary documentation for product registration with EDA to obtain the required approvals for labeling & packaging. This includes providing data on the safety, efficacy, and quality of the product and managing any changes to the product’s formulation, manufacturing process, or labeling which needs to be approved by the authorities before they can be implemented.

Our Team serves as a liaison between the company and regulatory authorities, handling communications, submissions, and responses to queries or concerns.

HF0165OA2940/112024

HF0165OA3115/122024

HDHMF0165OA3309/012025

3. Manufacturing:

Once regulatory approval is obtained, the drug moves into manufacturing. This involves large-scale production of the drug following strict quality control measures.

HF0165OA2940/112024

HF0165OA3115/122024

HDHMF0165OA3309/012025

4. Quality Control:

Throughout the manufacturing process, quality control checks ensure that the drug meets strict standards for potency, purity, and stability. These checks continue even after the product is on the market to ensure consistency and safety.

HF0165OA2940/112024

HF0165OA3115/122024

HDHMF0165OA3309/012025

5. Distribution and Marketing:

Once manufactured and approved, pharmaceutical products are distributed to pharmacies, hospitals, and other healthcare providers. We use marketing efforts to promote the products to healthcare professionals and consumers.

HF0165OA2940/112024

HF0165OA3115/122024

HDHMF0165OA3309/012025

Let’s work together

Export Capabilites

Marcyrl Pharmaceutical Industries, an Egyptian pharmaceutical manufacturer, has secured investment from Development Partners International (DPI) and Amethis. They focus on specialty generics, to improve access to critical care drugs across Africa. Marcyrl’s growth includes expanding its product portfolio and addressing the demand for affordable specialty generics in Africa. The investment underscores the significance of the pharmaceutical sector and Marcyrl’s commitment to bridging healthcare gaps in the continent.

Capitalizing on our EU-approved GMP sites, Marcyrl Pharmaceutical Industries is exporting a wide range portfolio of medicines to 23 export markets including GCC, LEVANT, and AFRICA

Our ambitious plan to expand our export business in Africa, CIS, GCC, and LATAM.

Why partner with Marcyrl

A Wide portfolio including a niche
in hormonal and respiratory

325 SKUs mainly in chronic disease areas; 300 SKUs in the pipeline A portfolio spanning 15 TAs, in particular female health/fertility, cardiovascular, urology, neuroscience, gastroenterology, etc. Niche in novel, high-complexity products (in particular hormonal, respiratory)

Why partner with Marcyrl

Wide portfolio including niche
in hormonal and respiratory products

Top-notch R&D and manufacturing capabilities with EU GMP-certified facilities Cost competitiveness built on world-class procurement and lean operations – Track record of effective cost containment despite sharp currency devaluation 2017-2021; Leadership in the tender market (11% of sales in 2021)

Why partner with Marcyrl

Track record of registering and
commercializing in export markets

Existing export footprint
in 23 countries outside of Egypt
107 successful registrations in export markets,
106 products under registration

Why partner with Marcyrl

Strong management team, backed by
leading institutional investors

Experienced management with diverse expertise
Entry of DPI and Amethis in 2023
- combined AUM of USD 3.6 billion,
Africa focused with strong pharma exposure